ERIN CASSIDY: Open Payments
NPI 1043401201 · ROSEBURG, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$694 in 57 payments from 13 companies in 2025. Trend: 2023 $232 · 2024 $424 · 2025 $694
Food & beverage: $694
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $205 |
| PFIZER INC. | 18 | $140 |
| AstraZeneca Pharmaceuticals LP | 5 | $76 |
| Actelion Pharmaceuticals US, Inc. | 1 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Novo Nordisk Inc | 2 | $34 |
| Amgen Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Edwards Lifesciences Corporation | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $21 |
Products named: LEQVIO, ELIQUIS, LOKELMA, OPSYNVI, Wegovy, REPATHA, AMVUTTRA, CAMZYOS.
Industry payments across OR — which companies pay providers there.
